Many reconstructed drugs are being used and tested on patients of Covid-19 in search of accurate treatment. The anti-inflammatory drug colchicine is also being seen as a possible treatment for Covid-19. Affordable, readily available colchicine is a drug used in the treatment of rheumatic and joint pain. The Drugs Controller General of India has approved the testing of the drug in the treatment of Covid-19 patients.
Council of Scientific and Industrial Research and Lakshai Life Sciences Pvt., Hyderabad. Ltd. will test. In the second phase of human trials, the efficacy and safety of the drug will be ascertained for Covid-19 patients. CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu will be the participants in the important human trial. Dr Ram Upadhyay, Chief Executive, Lakshai Life Sciences said that the enrollment of patients for the trial has already started in many places in India and is expected to be completed in the next 8-10 weeks.
Many international research has indicated that many patients have lost their lives due to cardiac complications during corona infection and post-covid syndrome. With the approval of DCGI, it has become necessary to find new or remanufactured drugs. CSIR experts believe that the colchicine drug would be an important therapeutic intervention for Covid patients with cardiac co-morbidities and to reduce proinflammatory cytokines, leading to a quicker recovery. India is the largest producer of Colchicine. This means that if the drug is found effective in the treatment of covid-19, then it is likely to be available to Kovid-19 patients at an affordable rate.
Last week, CSIR launched Lakshai Life Sciences Pvt. Ltd. had announced to start the second phase of human trials of the anti-worm drug niclosamide for the treatment of covid-19. CSIR said that in the past, Niclosamide has been extensively used in adults as well as children. The safety aspect of this drug has been investigated and found to be safe for human consumption at different dosage levels.